Amplifon (AMFPF) & Its Peers Critical Comparison

Amplifon (OTCMKTS:AMFPF) is one of 95 publicly-traded companies in the “Medical Services” industry, but how does it weigh in compared to its rivals? We will compare Amplifon to similar companies based on the strength of its earnings, dividends, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Amplifon and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amplifon	5.90%	13.68%	3.97%
Amplifon Competitors	-747.65%	-29.71%	-13.76%

Insider and Institutional Ownership

57.3% of shares of all “Medical Services” companies are owned by institutional investors. 12.9% of shares of all “Medical Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Amplifon has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Amplifon’s rivals have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Amplifon and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amplifon	0	1	1	0	2.50
Amplifon Competitors	419	2238	4789	151	2.61

As a group, “Medical Services” companies have a potential upside of 434.29%. Given Amplifon’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Amplifon has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Amplifon and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amplifon	$2.61 billion	$157.31 million	35.07
Amplifon Competitors	$12.81 billion	$234.98 million	1.70

Amplifon’s rivals have higher revenue and earnings than Amplifon. Amplifon is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Amplifon rivals beat Amplifon on 9 of the 13 factors compared.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.